Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

257.12
+2.120.83%
Post-market: 257.600.4800+0.19%19:57 EDT
Volume:4.31M
Turnover:1.11B
Market Cap:454.43B
PE:72.64
High:259.61
Open:253.92
Low:253.92
Close:255.00
52wk High:267.47
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:1.00
T/O Rate:0.24%
Dividend:6.83
Dividend Rate:2.66%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-76.57
PE(LYR):108.95

Loading ...

AbbVie Announces Q4 2026 Dividend of R$ 0.37 Per Unit, Payable Nov. 23

Reuters
·
Yesterday

AbbVie’s ECLIPSE Migraine Trial Completes, Setting Up a New Catalyst for ABBV

TIPRANKS
·
Yesterday

Analysts’ Top Healthcare Picks: Adagene (ADAG), AbbVie (ABBV)

TIPRANKS
·
Sep 11

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 11

AbbVie Keeps Quarterly Dividend at $1.73 a Share, Payable Nov. 16 to Holders of Record Oct. 15

MT Newswires Live
·
Sep 11

AbbVie Declares Quarterly Cash Dividend of $1.73 a Share

Reuters
·
Sep 11

Abbvie - Declares Qtrly Cash Dividend of $1.73 Per Share

THOMSON REUTERS
·
Sep 11

AbbVie’s Eye Implant Study Delivers Fresh Real‑World Clarity for Investors

TIPRANKS
·
Sep 11

AbbVie Says Atogepant Met Primary, Secondary Endpoints in Phase 3 Menstrual Migraine Study

MT Newswires Live
·
Sep 10

AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine

TIPRANKS
·
Sep 10

Abbvie - Atogepant Safety Results Consistent with Known Profile; no New Safety Signals

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Meets Primary and All Eight Ranked Secondary Endpoints in Phase 3 Luna Study

THOMSON REUTERS
·
Sep 10

Abbvie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Shows Significant Improvements Across Multiple Endpoints Versus Placebo

THOMSON REUTERS
·
Sep 10

Abbvie Exec Says Strong Balance Sheet and Long Growth Runway Allow Company to Consider Both Early- and Late-Stage Business Development Opportunities - Conf Call

THOMSON REUTERS
·
Sep 09

Abbvie Exec Says Expects Approval of Subcutaneous Crohn's Disease Treatment in Q4 - Conf Call

THOMSON REUTERS
·
Sep 09

Movement Alert|AbbVie Falls 3.13% in Regular Trading, Trading at $248.79

Market Focus
·
Sep 09

Headlands Research Names Brandon Pallott Chief Commercial Officer

Reuters
·
Sep 09

BofA Securities Adjusts Price Target on AbbVie to $282 From $276

MT Newswires Live
·
Sep 08

AbbVie price target raised to $282 from $276 at BofA

TIPRANKS
·
Sep 08